142 related articles for article (PubMed ID: 31426129)
21. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
22. PEDF reduces malignant cells proliferation and inhibits the progression of myelofibrosis in myeloproliferative neoplasms.
Li Y; Gao H; Dong H; Wang W; Xu Z; Wang G; Liu Y; Wang H; Ju W; Qiao J; Xu K; Fu C; Zeng L
Biochem Pharmacol; 2022 May; 199():115013. PubMed ID: 35318038
[TBL] [Abstract][Full Text] [Related]
23. Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations.
Lekovic D; Gotic M; Skoda R; Beleslin-Cokic B; Milic N; Mitrovic-Ajtic O; Nienhold R; Sefer D; Suboticki T; Buac M; Markovic D; Diklic M; Cokic VP
Ann Hematol; 2017 Mar; 96(3):393-404. PubMed ID: 27924369
[TBL] [Abstract][Full Text] [Related]
24. Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations.
Guo BB; Allcock RJ; Mirzai B; Malherbe JA; Choudry FA; Frontini M; Chuah H; Liang J; Kavanagh SE; Howman R; Ouwehand WH; Fuller KA; Erber WN
Am J Pathol; 2017 Jul; 187(7):1512-1522. PubMed ID: 28502479
[TBL] [Abstract][Full Text] [Related]
25. [The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features].
Borovecki A; Skrtić A; Paro MM; Lasan R; Dominis M
Acta Med Croatica; 2011 Sep; 65 Suppl 1():31-6. PubMed ID: 23126027
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic factors and survival in chronic myeloproliferative disorders].
Kvasnicka HM; Thiele J; Schmitt-Graeff A; Schaefer HE
Pathologe; 2000 Jan; 21(1):63-72. PubMed ID: 10663670
[TBL] [Abstract][Full Text] [Related]
27. Angiogenic factors are increased in circulating granulocytes and CD34
Subotički T; Mitrović Ajtić O; Beleslin-Čokić BB; Nienhold R; Diklić M; Djikić D; Leković D; Bulat T; Marković D; Gotić M; Noguchi CT; Schechter AN; Skoda RC; Čokić VP
Mol Carcinog; 2017 Feb; 56(2):567-579. PubMed ID: 27341002
[TBL] [Abstract][Full Text] [Related]
28. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Wehmeier A; Südhoff T; Meierkord F
Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
[TBL] [Abstract][Full Text] [Related]
29. Megakaryocytes and platelets in myeloproliferative disorders.
Briere J; Kiladjian JJ; Peynaud-Debayle E
Baillieres Clin Haematol; 1997 Feb; 10(1):65-88. PubMed ID: 9154316
[TBL] [Abstract][Full Text] [Related]
30. Platelet peroxidase deficiency in a case of myelodysplastic syndrome with myelofibrosis.
Imbert M; Jarry MT; Tulliez M; Breton-Gorius J
J Clin Pathol; 1983 Nov; 36(11):1223-8. PubMed ID: 6630573
[TBL] [Abstract][Full Text] [Related]
31. [Selected parameters of blood platelet function in patients with myeloproliferative syndrome].
Zuk E
Ann Acad Med Stetin; 1998; 44():137-54. PubMed ID: 9857536
[TBL] [Abstract][Full Text] [Related]
32. The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis.
Pizzi M; Gergis U; Chaviano F; Orazi A
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):96-104. PubMed ID: 27521149
[TBL] [Abstract][Full Text] [Related]
33. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
Thiele J; Kvasnicka HM; Fuchs N; Brunnbauer K; Volkwein N; Schmitt-Graeff A
Haematologica; 2003 Oct; 88(10):1130-8. PubMed ID: 14555309
[TBL] [Abstract][Full Text] [Related]
34. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
Tovar-Bobadilla JL; Ortiz-Hidalgo C
Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
[TBL] [Abstract][Full Text] [Related]
35. Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders.
Romano M; Viero P; Cortellazzo S; Barbui T; Donati MB; Poggi A
Haemostasis; 1990; 20(3):162-8. PubMed ID: 2143744
[TBL] [Abstract][Full Text] [Related]
36. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
37. Mixed myelodysplastic syndrome and myeloproliferative disorder with bone marrow and pulmonary fibrosis: the role of megakaryocytes.
Rosenstingl S; Brouland JP; Zini JM; Tobelem G; Dupuy E
Acta Haematol; 2003; 109(3):145-9. PubMed ID: 12714825
[TBL] [Abstract][Full Text] [Related]
38. Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: deconstructing a myth?
Barosi G; Gale RP
Leuk Res; 2011 May; 35(5):563-5. PubMed ID: 21296418
[TBL] [Abstract][Full Text] [Related]
39. Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukaemia with bone marrow fibrosis.
Hussein K; Stucki-Koch A; Göhring G; Kreipe H; Suttorp M
Leukemia; 2017 Jul; 31(7):1540-1546. PubMed ID: 28239144
[TBL] [Abstract][Full Text] [Related]
40. Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens.
Seetharam SM; Liu Y; Wu J; Fechter L; Murugesan K; Maecker H; Gotlib J; Zehnder J; Paulmurugan R; Krishnan A
Blood Adv; 2023 Sep; 7(18):5433-5445. PubMed ID: 37315179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]